Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.

Abstract

Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete regression; two patients had stable disease; and 35 patients had disease progression. The toxicity, which was primarily hematologic, was acceptable.

• Authors: R H Creech, R B Catalano, K M Dierks, M K Shah
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 68 Issue 12 Pg. 1499-501 (Dec 1984) ISSN: 0361-5960 [Print] United States
• PMID: 6548936 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Receptors, Estrogen
• Cyclophosphamide
• Mitolactol
• Fluorouracil
• Methotrexate

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy)
• Cyclophosphamide (administration & dosage)
• Drug Evaluation
• Female
• Fluorouracil (administration & dosage)
• Humans
• Methotrexate (administration & dosage)
• Middle Aged
• Mitolactol (therapeutic use, toxicity)
• Neoplasm Metastasis
• Receptors, Estrogen (analysis)